Skip to content

Impact of Incomplete Endometrial Ablation

The Impact of Incomplete Endometrial Ablation on the Success Rate of Novasure Endometrial Ablation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06122363
Enrollment
121
Registered
2023-11-08
Start date
2023-03-01
Completion date
2025-12-30
Last updated
2025-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heavy Menstrual Bleeding

Brief summary

The aim of the proposed protocol is to study the impact of incomplete endometrial ablation on the PBAC score, reintervention, satisfaction, controlled bleeding and dysmenorrhea at 24 months after Novasure endometrial ablation, in women with heavy menstrual bleeding treated at Máxima Medical Centre Veldhoven, in The Netherlands.

Detailed description

The primary outcome is blood loss at 24 months after treatment, measured with the PBAC-score according to Higham. To calculate this score women were asked, in the MIRA and MIRA2 study, to record their menstrual blood loss for one month counting the number of super tampons or pads used each day. The total score was calculated using a score of 1 for each lightly saturated tampons. For pads the scores were respectively 1, 5 and 20. Secondary outcome measures were controlled bleeding, defined as a PBAC-score not exceeding 75 points, PBAC score of zero, re-intervention rate 24 months after treatment, satisfaction with treatment (measured with a 5-point Likert scale) and dysmenorrhea. In addition, multiple variables were analyzed in predicting the occurrence of incomplete endometrial ablation, including age, BMI, cavum length, cavum width, ablation time, ablation power, nulliparity, sterilization in history, section caesarea in history, position of the uterus (AVF/RVF), presence of myomas, the presence of adenomyosis and surgery under local anesthesia, generally without sterilization or generally in combination with sterilization. Information was collected from EPD and the MIRA and MIRA2 databases.

Interventions

DEVICEhysteroscopy

uterine hysteroscopy right after Novasure endometrial ablation

Sponsors

Maxima Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Endometrial ablation between 2012 and 2023 in Máxima Medical Centre * Women had to suffer from heavy menstrual bleeding

Exclusion criteria

\- No saved hysteroscopy images or bad quality hysteroscopy images

Design outcomes

Primary

MeasureTime frameDescription
Pictorial Blood Assessment Chart (PBAC) score24 monthsBlood loss of 1 month, measured by the number of needed tampons/pads and how heavily they are filled with blood. The higher the score, the more severe blood loss. From 150 points the amount is defined as heavy menstrual bleeding.

Secondary

MeasureTime frameDescription
Rate of reintervention24 monthsSurgical and Medical reintervention
Dysmennorrhea24 monthsPresence of dysmennorrhea. Categorized as absence, mild, moderate and severe.
Number of patients having controlled bleeding24 monthsPictorial Blood Assessment Chart (PBAC) score less than 75.
Satisfaction of the patient with the treatment24 monthsSatisfaction measured with a 5-point Likert scale. 1=very unsatisfied, 2= unsatisfied, 3= neutraal, 4= satisfied, 5= very satisfied.

Other

MeasureTime frameDescription
Number of possible prognostic variables predicting the occurrence of incomplete endometrial ablation.baselineAge, BMI, cavum length, cavum width, ablation time, ablation power, nulliparity, sterilization in history, section caesarea in history, position of the uterus (AVF/RVF), presence of myomas, the presence of adenomyosis and surgery under local anesthesia, generally without sterilization or generally in combination with sterilization

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026